Merck Sharp + Dohme Corp.

The Dupont Merck Pharmaceutical Company

Bristol-myers Squibb Pharma Company

Albany Molecular Research, Inc.

Bristol-myers Squibb Compnay

Amr Technology, Inc.

Other

Gilead Connecticut, Inc.

Merck Gmbh

Cgi Pharmaceuticals, Inc.

Bristol-myers Squibb Pharma Corporation

Matthew Ernst Voss

Stephane L Bogen

Ronald J Doll

Jingwu Duan

Ian L Scott

Manami Shizuka

Jeffrey M Ralph

Carl P Decicco

Michelle R Machacek

B Wesley Trotter

Christopher Francis Thompson

Michael Hale Reutershan

Francesc Xavier Fradera Llinas

Matthew Christopher

Yaolin Wang

Latha G Nair

Binyuan Sun

Weidong Pan

Michelle Martinez

Michael D Altman

Gerald Wayne Shipps, Jr

Gregory R Ott

Craig R Gibeau

Yuan Tian

Liping Yang

Yao Ma

Brian Robert Lahue

Scott A Mitchell

Timothy J Guzi

Peter A Blomgren

Christopher J Dinsmore

Thomas P Maduskuie, Jr

David R Brittelli

Wendell W Wilkerson

Richard A Earl

Pavel E Zhichkin

Mihaela Diana Danca

Lihua Chen

Yuan Liu

James H Jensen

Xiao Tao Chen

Timothy D Costello

Leon De Brabander, Jr

Mark A McCoy

Margarita Kirova-Snover

Malcolm MacCoss

Chu-Biao Xue

Douglas G Batt

William John Pitts

John Wityak

Robert J Cherney

Corey Strickland

Percy H Carter

Malcolm Maccoss

Ruth Richmond Wexler

Prabhakar Kondaji Jadhav

Zhuyan Guo

Bheemashankar A Kulkarni

Zhonghui Lu

Rumin Zhang

Christopher A Teleha

Gerald W Shipps

Chaomin Li

Carolyn Michele Cammarano

Amin Nomeir

Ying Song

Joanne Marie Smallheer

Dietrich P Steinhuebel

Giovanna Scapin

Bryan W King

Danny J Hicklin

Amit Ashokro Kudale

Jagannath Panda

Anthappan Tony Kurissery

W Bent Clayton

Diane Rindgen

Cynthia Seidel-Dugan

Elise M Siegel

The present invention provides 2,6,7 substituted purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

2,6,7 substituted purines as HDM2 inhibitors

The present invention provides substituted pyrrolopyrimidines of Formula I as described herein or a pharmaceutically acceptable salt or solvate thereof: The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Substituted pyrrolopyrimidines as HDM2 inhibitors

The present invention provides 2,6,7,8 Substituted Purines as described herein or a pharmaceutically acceptable salt thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

2,6,7,8 substituted purines as HDM2 inhibitors

The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. 

Substituted piperidines as HDM2 inhibitors

The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

Substituted imidazopyridines as HDM2 inhibitors

The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed.

[object Object]

The present invention provides a compound of Formula 1 as described herein or a pharmaceutically acceptable salt, solvate or ester thereof. The compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same.

Substituted piperidines that increase p53 activity and the uses thereof

Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one chemical entity as a single active agent or administering such at least one chemical entity in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one chemical entity under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.

Certain substituted ureas, as modulators of kinase activity

The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.

Vinorelbine derivatives

In its many embodiments, the present invention discloses novel compounds, as inhibitors of HDM2 protein methods for preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of treatment, prevention, inhibition, of one or more diseases associated with the HDM2 protein or P53 using such compounds or pharmaceutical compositions.

Substituted piperidines that increase P53 activity and the uses thereof

Vinca derivatives

The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.

Lactams as modulators of chemokine receptor activity

Growing community of inventors

Nassau, NY, United States of America

Matthew Ernst Voss